# Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

> **NCT00954226** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Recurrent Head and Neck Carcinoma
- Recurrent Salivary Gland Carcinoma
- Recurrent Skin Carcinoma
- Skin Squamous Cell Carcinoma

## Interventions

- **DRUG:** Erlotinib Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00954226
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-05
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00954226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00954226, "Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00954226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*